Kidney disease drug study: how does cenerimod behave?

NCT ID NCT05004311

Completed Knowledge-focused Sponsor: Viatris Innovation GmbH Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at how the drug cenerimod is processed in people with severe kidney impairment compared to healthy people. A total of 16 participants took a single 0.5 mg dose of cenerimod. Researchers measured drug levels in the blood and checked safety markers like heart rhythm and blood pressure. The goal was to understand if kidney problems change how the drug works, which could guide future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cenerimod
What this could lead to: If successful, this study could help doctors understand how to dose cenerimod safely in patients with severe kidney disease.
What could go wrong: This is a very early, small study (16 people) focused on drug levels, not on treating any disease. Results may not apply to broader populations or predict long-term safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY RENAL IMPAIRMENT

Contacts and locations

Locations

BlueClinical Phase 1 Hospital de Prelado

Porto, 4250-449, Portugal

More trials for these conditions

Other studies related to the condition(s) this trial covers.